{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:49:57Z","timestamp":1779162597406,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02676-4","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T03:02:52Z","timestamp":1678158172000},"page":"2777-2785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Age of onset and factors affecting treatment responses in ocular myasthenia gravis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7153-0813","authenticated-orcid":false,"given":"Parinee","family":"Kemchoknatee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyarak","family":"Armornpetchsathaporn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duanghathai","family":"Tangon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thansit","family":"Srisombut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"issue":"26","key":"2676_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"issue":"1","key":"2676_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF et al (2018) Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 128(1):15\u201324. https:\/\/doi.org\/10.1080\/00207454.2017.1344237","journal-title":"Int J Neurosci"},{"issue":"10","key":"2676_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","volume":"72","author":"CE Peeler","year":"2015","unstructured":"Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT (2015) Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol 72(10):1170\u20131174. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1444","journal-title":"JAMA Neurol"},{"issue":"1","key":"2676_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M (2017) Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 17(1):77. https:\/\/doi.org\/10.1186\/s12883-017-0857-7","journal-title":"BMC Neurol"},{"issue":"1","key":"2676_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/01616412.2018.1525121","volume":"41","author":"L Fan","year":"2019","unstructured":"Fan L, Ma S, Yang Y, Yan Z, Li J, Li Z (2019) Clinical differences of early and late-onset myasthenia gravis in 985 patients. Neurol Res 41(1):45\u201351. https:\/\/doi.org\/10.1080\/01616412.2018.1525121","journal-title":"Neurol Res"},{"issue":"1","key":"2676_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki III","year":"2000","unstructured":"Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"issue":"6","key":"2676_CR7","first-page":"497","volume":"38","author":"KE Osserman","year":"1971","unstructured":"Osserman KE, Genkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38(6):497\u2013537","journal-title":"Mt Sinai J Med"},{"issue":"5","key":"2676_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/jnnp.56.5.496","volume":"56","author":"FE Somnier","year":"1993","unstructured":"Somnier FE (1993) Clinical implementation of anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 56(5):496\u2013504. https:\/\/doi.org\/10.1136\/jnnp.56.5.496","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2676_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","volume":"267","author":"J Rath","year":"2020","unstructured":"Rath J, Brunner I, Tomschik M, Zulehner G, Hilger E, Krenn M et al (2020) Frequency and clinical features of treatment-refractory myasthenia gravis. J Neurol 267(4):1004\u20131011. https:\/\/doi.org\/10.1007\/s00415-019-09667-5","journal-title":"J Neurol"},{"issue":"11","key":"2676_CR10","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/wnl.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94(11):e1171\u2013e1180. https:\/\/doi.org\/10.1212\/wnl.0000000000008903","journal-title":"Neurology"},{"issue":"1","key":"2676_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","volume":"230","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N (2011) Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230(1):148\u2013152. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.10.023","journal-title":"J Neuroimmunol"},{"issue":"1","key":"2676_CR12","first-page":"13","volume":"25","author":"N Chirapapaisan","year":"2007","unstructured":"Chirapapaisan N, Tanormrod S, Chuenkongkaew W (2007) Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis. Asian Pac J Allergy Immunol 25(1):13\u201316","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"10 Suppl 4","key":"2676_CR13","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","volume":"5","author":"EA Engels","year":"2010","unstructured":"Engels EA (2010) Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5(10 Suppl 4):S260\u2013S265. https:\/\/doi.org\/10.1097\/JTO.0b013e3181f1f62d","journal-title":"J Thorac Oncol"},{"issue":"7","key":"2676_CR14","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER (2015) Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 122(7):1517\u20131521. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.010","journal-title":"Ophthalmology"},{"issue":"3","key":"2676_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, McDermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ et al (2016) Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 53(3):363\u2013369. https:\/\/doi.org\/10.1002\/mus.24769","journal-title":"Muscle Nerve"},{"issue":"5","key":"2676_CR16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneur.57.5.752","volume":"57","author":"HJ Kaminski","year":"2000","unstructured":"Kaminski HJ, Daroff RB (2000) Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 57(5):752\u2013753. https:\/\/doi.org\/10.1001\/archneur.57.5.752","journal-title":"Arch Neurol"},{"issue":"8","key":"2676_CR17","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ene.13040","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Meng Y, Li HF, Hong Y, Sun L, Zhu X et al (2016) GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis. Eur J Neurol 23(8):1372\u20131379. https:\/\/doi.org\/10.1111\/ene.13040","journal-title":"Eur J Neurol"},{"key":"2676_CR18","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2147\/opth.S261259","volume":"14","author":"T Threetong","year":"2020","unstructured":"Threetong T, Poonyathalang A, Preechawat P, Jindahra P, Padungkiatsagul T, Vanikieti K (2020) Initial treatment response in ocular myasthenia gravis: a comparison between low and moderate doses of prednisolone. Clin Ophthalmol 14:2051\u20132056. https:\/\/doi.org\/10.2147\/opth.S261259","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"2676_CR19","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/wnl.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Grav Study Gr Neurol 50(6):1778\u20131783. https:\/\/doi.org\/10.1212\/wnl.50.6.1778","journal-title":"Myasthenia Grav Study Gr Neurol"},{"issue":"12","key":"2676_CR20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48(12):1246\u20131252. https:\/\/doi.org\/10.1136\/jnnp.48.12.1246","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2676_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12883-019-1397-0","volume":"19","author":"CC Chou","year":"2019","unstructured":"Chou CC, Su IC, Chou IJ, Lin JJ, Lan SY, Wang YS et al (2019) Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study. BMC Neurol 19(1):170. https:\/\/doi.org\/10.1186\/s12883-019-1397-0","journal-title":"BMC Neurol"},{"issue":"1\u20132","key":"2676_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"YH Hong","year":"2008","unstructured":"Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK et al (2008) Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 273(1\u20132):10\u201314. https:\/\/doi.org\/10.1016\/j.jns.2008.05.023","journal-title":"J Neurol Sci"},{"issue":"1","key":"2676_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1055\/s-2004-829589","volume":"24","author":"A Vincent","year":"2004","unstructured":"Vincent A, McConville J, Farrugia ME, Newsom-Davis J (2004) Seronegative myasthenia gravis. Semin Neurol 24(1):125\u2013133. https:\/\/doi.org\/10.1055\/s-2004-829589","journal-title":"Semin Neurol"},{"issue":"5","key":"2676_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.20854","volume":"36","author":"KH Chan","year":"2007","unstructured":"Chan KH, Lachance DH, Harper CM, Lennon VA (2007) Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 36(5):651\u2013658. https:\/\/doi.org\/10.1002\/mus.20854","journal-title":"Muscle Nerve"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02676-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02676-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02676-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T02:04:31Z","timestamp":1690423471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02676-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2676"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02676-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"30 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by Rajavithi Hospital Research Ethics Committee, EC number 195\/2564. All the patients provided written informed consent before data were collected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants were given a written informed consent before data collection process.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}